What Мастодинон Treats: Main Uses and Benefits

The primary therapeutic role of Мастодинон is to provide supportive relief and symptomatic assistance for recurrent, non-pathological issues in women's health. For instance, the main active component, Vitex agnus-castus, is recognized for its role in addressing premenstrual syndrome. It is used across conditions characterized by episodic or fluctuating symptom patterns tied to the menstrual cycle.

Easing Cyclical Discomfort and PMS

This preparation is commonly applied in clinical settings marked by cyclical mastalgia, Premenstrual Syndrome (PMS), and minor menstrual cycle rhythm disturbances. It helps manage distressing physical manifestations like pain, swelling, and tension in the breast tissue, alongside emotional symptoms such as irritability and nervousness. The medication is commonly used to help with symptomatic assistance during phases of increased distress. This supportive management contributes to easing the overall symptom load during the premenstrual phase, assisting with maintaining functional stability when symptoms are more noticeable.

---

Quick Fact: Support for Cyclical Breast Tension

The official regulatory documentation strictly limits the use of Мастодинон to adult women over 18 years of age. Eligibility is based on age, physiological status, and ingredient sensitivity.

Eligibility Scope

Classification	Population Restriction
Allowed	Adult women over 18 years of age.
Contraindicated	Pregnancy; Children and adolescents under 18; Patients who have not yet started regular menstruation; Known hypersensitivity to any component.
Not Recommended	Women who are breastfeeding (lactation).

Eligibility-Related Restrictions

• Pediatric Use: Use is prohibited for individuals under 18 years due to a lack of sufficient data regarding safety and efficacy in this age group.
• Reproductive Caution: Use during pregnancy is contraindicated as there are no indications for its use. Use is not recommended while breastfeeding due to the potential to affect lactation.
• Fertility: The active component may affect fertility, and the use of contraception is recommended if pregnancy is not planned during treatment.
• Excipient-Based: The tablet form is restricted for patients with lactose intolerance. The oral drops require caution due to their high ethanol content.

Interactions with other medicines and products

The official regulatory profile for Мастодинон outlines specific documented interactions focused on the product's classification and the biological activity of its key component, Agnus Castus. This profile emphasizes pharmacodynamic considerations and general substance interference, rather than metabolic enzyme pathways.

---

Documented Medicinal Product Interactions

A potential pharmacodynamic interaction is officially documented with several categories of medicinal products. Because of the oestrogenic and dopaminergic properties associated with Agnus Castus, risks related to co-administration cannot be formally excluded with agents that operate on the same hormonal axes.

The regulatory documents specifically note the need for caution with medicines classified as:

• Dopamine agonists and Dopamine antagonists
• Oestrogens and Anti-oestrogens

The product labeling does not include a formal list of contraindicated substances for co-administration. Furthermore, official sources do not document any interactions involving CYP enzymes, drug transporters, specific timing requirements, or modifications to drug exposure levels (AUC/Cmax).

---

Substance and Lifestyle Constraints

Official regulatory information also defines constraints related to external factors that may impact efficacy. The effect of the homeopathic preparation may be negatively influenced by the consumption of common stimulants and irritants, specifically including coffee and alcohol. Generally harmful factors in an individual’s lifestyle are also officially cited as potentially diminishing the product’s intended effect.

The mechanism is driven by the dopaminergic action of its primary component, which influences the central regulation of reproductive hormones. This mechanism is defined by specific molecular interactions and resulting systemic physiological changes.

Dopamine D2 Receptor Agonism in the Pituitary

This mechanism involves the initial molecular step: the diterpene components of Agnus Castus act as agonists on D2 receptors located on lactotrophic cells in the anterior pituitary gland. Activation of these receptors reinforces the natural inhibitory signal for the production and release of Prolactin ( PRL). This action directly engages the neuroendocrine pathway that regulates PRL secretion.

Suppression of Prolactin and Tissue Modulation

The systemic consequence of sustained D2 R agonism is decreased systemic levels of Prolactin in functional states. Since PRL is a key hormonal stimulus for proliferation and fluid retention in mammary gland tissue, the consequence is a decrease in PRL-mediated proliferative signaling. This reduction in PRL-mediated stimulation is the physiological consequence that results in the modulation of tissue dynamics.

Mechanism Constraint: Required Sustained Action

The full physiological outcome of the D2 R agonism mechanism is slow-onset, requiring sustained pathway engagement over several weeks. This constraint is due to the nature of hormonal regulation and the time necessary for the continuous suppression of PRL to translate into measurable tissue-level adjustments within the mammary glands.

The official usage of Мастодинон is strictly defined by regulatory documents, establishing a standardized, non-interruptible treatment protocol for adult women. This complex phyto-homeopathic product is administered exclusively via the oral route and is available as tablets and oral drops.

The labeled administration protocol details the necessary frequency, dose, and duration:

---

Administration Scope

Property	Official Instruction
Dosing Schedule	1 tablet or 30 drops per dose.
Frequency	Twice daily (morning and evening).
Duration	At least 3 months (continuous use, including during menstrual bleeding).

---

The tablets should be taken with a small amount of liquid, and the drops must be diluted with a small amount of water prior to intake.

Procedural Constraints

Constraint	Rule
Age-Group Rule	Intended for adult women. Use is not established for children under the age of 12 years.
Missed Dose Rule	Do not take a double dose to compensate for a forgotten dose.

---

Connection to the overall use protocol (2–4 sentences): The regulatory documents establish a standardized, twice-daily oral regimen with a fixed dose. This protocol is defined by a mandatory minimum duration of three months and a continuous dosing pattern that is not interrupted by the menstrual cycle, outlining the high-level usage structure approved by health authorities.

Mastodynon: Recent Clinical Evidence

Clinical evidence for Mastodynon primarily focuses on its main active ingredient, a standardized extract of Vitex agnus-castus (chaste tree), and its traditional gynecological uses. Research efforts have been directed toward evaluating its association with improvements in symptoms related to the menstrual cycle.

---

Efficacy in Premenstrual Symptoms and Breast Pain

Randomized controlled trials (RCTs) and systematic reviews have investigated the extract's effect on Premenstrual Syndrome (PMS) and cyclic mastalgia (breast pain). Findings from these studies suggest that the extract may be associated with a reduction in the severity of several PMS symptoms, particularly breast tenderness and pain.

Comparative studies have also explored the extract's potential role in managing cyclical breast pain over a period of several menstrual cycles, with some research indicating a favorable patient response when compared to placebo.

---

Research on Hormonal Factors

Research has explored the mechanism of action, suggesting that compounds within the extract may act on the pituitary gland to potentially affect the release of prolactin, a hormone linked to breast tenderness. Some clinical data shows that use of the extract is associated with a decrease in elevated prolactin levels in patients with latent hyperprolactinemia.

---

Tolerability and Comparative Safety

Across multiple studies, the primary ingredient is generally reported to be well-tolerated. Adverse events reported are typically mild and reversible, most commonly including headache, nausea, and mild gastrointestinal issues. Some trials comparing the extract to synthetic dopaminergic agents noted a lower incidence of adverse events with the herbal preparation, supporting its favorable tolerability profile.

Common questions about Мастодинон (FAQ)

Q: Can I use this medication for my child who is 2 years old?

According to the official product labeling for over-the-counter children's acetaminophen, specific dosing instructions are typically provided for children based on weight and age. For children under 2 years of age or under 24 pounds, consumers are instructed to consult a doctor before use.

Q: Is it safe to use this medicine for a long period of time?

The regulatory product labeling states that the user should stop use and consult a healthcare professional if pain worsens or lasts more than 10 days (for adults) or more than 5 days (for children under 12), or if fever persists for more than 3 days. These label instructions are provided because ongoing symptoms may indicate a condition requiring specific medical evaluation.

Q: Can I take this for migraines?

Some products that contain acetaminophen are available as combination medicines with other active ingredients, such as aspirin and caffeine. The official labeling for these specific combination products indicates that they are for the treatment of migraine headaches.

Q: Does this medicine affect pregnancy or breastfeeding?

The official Drug Facts labeling includes specific information regarding use during pregnancy and breastfeeding. The labeling states that individuals who are pregnant or breastfeeding should consult a health professional before using the product.

How to Store and Dispose of Мастодинон

Official regulatory documentation defines specific conditions for storing and disposing of this medicinal product to ensure its quality and safety.

Storage Requirements

Condition	Requirement
Temperature	Store at a temperature not exceeding 25 C.
Light Protection	Store in the original outer carton to protect the product from light.
Handling	The product must not be frozen. The bottle of drops must be kept tightly closed.

The medicine must be stored out of the sight and reach of children.

Stability and Disposal

The oral drops have an in-use shelf-life of 6 months after the initial opening, provided the storage temperature is maintained below 25 C. The product must not be used after the labeled expiration date.

Disposal of any unused or expired medicinal product and waste material must be carried out in accordance with local regulatory requirements. Medicines should generally not be disposed of via wastewater or household trash.